Screener
Fulgent Genetics, Inc. FLGT Therapeutic Development — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
FAQ
- What is Fulgent Genetics, Inc.'s therapeutic development — D&A?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — D&A of $143K in Q1 2026.
- How has Fulgent Genetics, Inc.'s therapeutic development — D&A changed year-over-year?
- Fulgent Genetics, Inc.'s therapeutic development — D&A decreased by 12.8% year-over-year, from $164K to $143K.
- What does therapeutic development — D&A mean?
- This reflects the non-cash expense allocated to the therapeutic development segment for the systematic allocation of the cost of tangible and intangible assets over their useful lives. It is essential for understanding the capital intensity and asset consumption of the segment.
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude